This Conceptual Note is part of the URM / Dynamic Medicine Series and interprets phase-dependent therapeutic efficacy in oncology as external clinical convergence with Reset-Window dynamics. The article is prompted by a randomized phase 3 trial of time-of-day immunochemotherapy in advanced non-small cell lung cancer, where earlier treatment administration was associated with improved progression-free and overall survival compared with later administration, without increased immune-related toxicity. The note does not claim that the trial validates URM. Instead, it argues that the findings support a broader dynamic medicine principle: identical or highly similar interventions may produce different clinical effects depending on the biological phase state of the system at the time of treatment. Established chronobiology and circadian immunology remain the primary explanatory frameworks. The URM / Reset-Window interpretation is used as a non-exclusive systems-level language for understanding state-dependent treatment responsiveness across immune, metabolic, autonomic, and oncologic systems. This work is conceptual and hypothesis-generating. It does not provide clinical treatment recommendations and should not be used to guide individual patient care without appropriate oncological expertise.
Anita Domargård (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: